FGFR1 fusions as a novel molecular driver in rhabdomyosarcoma
- 12 April 2024
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 63 (4) , e23232
Abstract
The wide application of RNA sequencing in clinical practice has allowed the discovery of novel fusion genes, which have contributed to a refined molecular classification of rhabdomyosarcoma (RMS). Most fusions in RMS result in aberrant transcription factors, such as PAX3/7::FOXO1 in alveolar RMS (ARMS) and fusions involving VGLL2 or NCOA2 in infantile spindle cell RMS. However, recurrent fusions driving oncogenic kinase activation have not been reported in RMS. Triggered by an index case of an unclassified RMS (overlapping features between ARMS and sclerosing RMS) with a novel FGFR1::ANK1 fusion, we reviewed our molecular files for cases harboring FGFR1‐related fusions. One additional case with an FGFR1::TACC1 fusion was identified in a tumor resembling embryonal RMS (ERMS) with anaplasia, but with no pathogenic variants in TP53 or DICER1 on germline testing. Both cases occurred in males, aged 7 and 24, and in the pelvis. The 2nd case also harbored additional alterations, including somatic TP53 and TET2 mutations. Two additional RMS cases (one unclassified, one ERMS) with FGFR1 overexpression but lacking FGFR1 fusions were identified by RNA sequencing. These two cases and the FGFR1::TACC1‐positive case clustered together with the ERMS group by RNAseq. This is the first report of RMS harboring recurrent FGFR1 fusions. However, it remains unclear if FGFR1 fusions define a novel subset of RMS or alternatively, whether this alteration can sporadically drive the pathogenesis of known RMS subtypes, such as ERMS. Additional larger series with integrated genomic and epigenetic datasets are needed for better subclassification, as the resulting oncogenic kinase activation underscores the potential for targeted therapy.Keywords
Funding Information
- National Institutes of Health
- Cycle for Survival
This publication has 38 references indexed in Scilit:
- FGFR1 gene fusions in a subset of pediatric mesenchymal tumors: Expanding the genetic spectrum of tumors sharing histologic overlap with infantile fibrosarcoma and “NTRK‐rearranged” spindle cell neoplasmsGenes, Chromosomes and Cancer, 2023
- Recurrent VGLL3 fusions define a distinctive subset of spindle cell rhabdomyosarcoma with an indolent clinical course and striking predilection for the head and neckGenes, Chromosomes and Cancer, 2022
- FGFR2::TACC2 fusion as a novel KIT‐independent mechanism of targeted therapy failure in a multidrug‐resistant gastrointestinal stromal tumorGenes, Chromosomes and Cancer, 2022
- The novel finding of an FGFR1::TACC1 fusion in an undifferentiated spindle cell sarcoma of soft tissue with aggressive clinical courseGenes, Chromosomes and Cancer, 2022
- Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committeeCancer Medicine, 2020
- Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS‐P WT GISTGenes, Chromosomes and Cancer, 2019
- Copy number alterations determined by single nucleotide polymorphism array testing in the clinical laboratory are indicative of gene fusions in pediatric cancer patientsGenes, Chromosomes and Cancer, 2017
- FGF Receptors: Cancer Biology and TherapeuticsMedicinal Research Reviews, 2013
- High‐resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well‐differentiated and dedifferentiated liposarcomaGenes, Chromosomes and Cancer, 2011
- FGFR1 over‐expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5′ CpG Island and abnormal expression of the AKT1, NOG, and BMP4 genesGenes, Chromosomes and Cancer, 2007